Sickle Cell Disease
📧 Sign up to get email alerts when something new happens for Sickle Cell Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Outcomes Mandate National Integration With Cannabis as Medicine [Phase 2]
Phase 2 clinical trial update focusing on integrating cannabis as medicine for various chronic pain conditions, with status currently UNKNOW…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Preventing Sickle Cell Kidney Disease [Phase 2]
Phase 2 clinical trial update on preventing sickle cell kidney disease; status terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies [Phase 1, Phase 2]
Phase 1/2 trial investigating NiCord allogeneic stem and progenitor cells for hemoglobinopathies (sickle cell disease and thalassemia).
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) [Phase 2]
Phase 2 trial of IMR-687 in adults with sickle cell disease (HbSS or Sickle-β0 thalassemia) has completed and results were posted on 2022-04…
-
CLINICAL_TRIALS trial_result · 2022-04-12Clinical Trial Update: Acupuncture for Adults With Sickle Cell Disease (SCD): A Feasibility Study [NA]
A feasibility study on acupuncture for adults with sickle cell disease was terminated; results were posted in 2022.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere [Phase 2]
Phase 2 trial update on hydroxyurea therapy aimed at optimizing access in pediatric patients; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia [Phase 2]
An extension study of IMR-687 in adults with sickle cell anemia (Phase 2) is ongoing.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa [Phase 3]
Phase 3 trial evaluating moderate-dose hydroxyurea for secondary stroke prevention in children with sickle cell disease in Sub-Saharan Afric…
-
CLINICAL_TRIALS trial_result · 2021-12-23Clinical Trial Update: Low Dose Ketamine and Acute Pain Crisis [Phase 4]
Phase 4 clinical trial update evaluating low-dose ketamine for acute pain crisis in sickle cell disease has completed.
-
FDA approval · 2021-12-17FDA Approved: OXBRYTA — Original Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)
FDA approves OXBRYTA (voxelotor) for the treatment of sickle cell disease in adults and pediatric patients aged 12 months and older. This or…
-
EMA approval · 2021-12-17New treatment for sickle cell disease
The EMA announces a new treatment for sickle cell disease, indicating a regulatory approval or positive assessment expanding options for pat…
-
FDA approval · 2021-12-17FDA Approved: OXBRYTA — Supplemental Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)
FDA approved a supplemental application for OXBRYTA (voxelotor) submitted by Global Blood Therapeutics, a Pfizer subsidiary, related to sick…
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease [Phase 3]
Phase 3 trial exploring hypnosis as a non-pharmacologic approach to manage pain and symptoms in sickle cell disease patients has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia [Phase 4]
Phase 4 clinical trial investigating hydroxycarbamide and L-Carnitine therapy in sickle cell disease has been completed.
-
CLINICAL_TRIALS trial_result · 2021-10-21Clinical Trial Update: Hydroxyurea and Transfusion [Phase 2]
Phase 2 clinical trial evaluating hydroxyurea and transfusion for sickle cell disease has been completed.
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Cardiovascular Complications of Sickle Cell Disease
Clinical trial update on cardiovascular complications in sickle cell disease with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) [Phase 4]
Phase 4 study evaluating how renal function affects the pharmacokinetics of SIKLOS (DARH) in sickle cell disease; completed with posted resu…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias [Phase 4]
Phase 4 clinical trial update on ferriprox for iron overload and sickle cell disease/other anemias; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease [Phase 2]
Phase 2 trial evaluating antioxidant therapy to reduce inflammation in sickle cell disease has completed with results posted.
-
EMA safety_alert · 2021-07-23CHMP endorses review finding no link between viral vector in Zynteglo and blood cancer
The CHMP endorses a review finding that there is no link between the viral vector used in Zynteglo and the development of blood cancer.
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Acceptability, Feasibility and Safety of a Yoga Program for Chronic Pain in Sickle Cell Disease [NA]
A terminated clinical trial evaluating acceptability, feasibility, and safety of a yoga program for chronic pain in sickle cell disease; res…
-
FDA approval · 2021-07-12FDA Approved: ADAKVEO — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for ADAKVEO (crizanlizumab) submitted by Novartis Pharmaceuticals Corporation. The action involves r…
-
EMA safety_alert · 2021-07-09EMA finds no evidence linking viral vector in Zynteglo to blood cancer
The EMA reports no evidence that the viral vector used in Zynteglo is linked to blood cancer, though continued monitoring is advised.
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies [Phase 2]
Phase 2 trial comparing intensive versus stable hydroxyurea dosing strategies in children with sickle cell anemia; results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) [Phase 3]
Phase 3 trial evaluating safety, tolerability, and immunogenicity of V116 in children with sickle cell disease has completed; results posted…